JP2015526446A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526446A5
JP2015526446A5 JP2015527590A JP2015527590A JP2015526446A5 JP 2015526446 A5 JP2015526446 A5 JP 2015526446A5 JP 2015527590 A JP2015527590 A JP 2015527590A JP 2015527590 A JP2015527590 A JP 2015527590A JP 2015526446 A5 JP2015526446 A5 JP 2015526446A5
Authority
JP
Japan
Prior art keywords
seq
antibody
peptide
bind
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526446A (ja
JP6664219B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2012/060684 external-priority patent/WO2013059373A2/en
Priority claimed from PCT/US2013/025981 external-priority patent/WO2013123084A1/en
Application filed filed Critical
Priority claimed from PCT/US2013/055015 external-priority patent/WO2014028668A2/en
Publication of JP2015526446A publication Critical patent/JP2015526446A/ja
Publication of JP2015526446A5 publication Critical patent/JP2015526446A5/ja
Application granted granted Critical
Publication of JP6664219B2 publication Critical patent/JP6664219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527590A 2012-08-14 2013-08-14 幹細胞増強治療法 Active JP6664219B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261683155P 2012-08-14 2012-08-14
US61/683,155 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US61/684,654 2012-08-17
US201261693712P 2012-08-27 2012-08-27
US61/693,712 2012-08-27
PCT/US2012/060684 WO2013059373A2 (en) 2011-10-17 2012-10-17 Media for stem cell proliferation and induction
USPCT/US2012/060684 2012-10-17
PCT/US2013/025981 WO2013123084A1 (en) 2012-02-13 2013-02-13 Method for detecting circulating fetal cells
USPCT/US2013/025981 2013-02-13
US201361837560P 2013-06-20 2013-06-20
US61/837,560 2013-06-20
PCT/US2013/055015 WO2014028668A2 (en) 2012-08-14 2013-08-14 Stem cell enhancing therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017238427A Division JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法

Publications (3)

Publication Number Publication Date
JP2015526446A JP2015526446A (ja) 2015-09-10
JP2015526446A5 true JP2015526446A5 (enExample) 2016-10-06
JP6664219B2 JP6664219B2 (ja) 2020-03-13

Family

ID=50101604

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015527590A Active JP6664219B2 (ja) 2012-08-14 2013-08-14 幹細胞増強治療法
JP2017238427A Active JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法
JP2020037396A Pending JP2020109101A (ja) 2012-08-14 2020-03-05 幹細胞増強治療法
JP2021181985A Pending JP2022025136A (ja) 2012-08-14 2021-11-08 幹細胞増強治療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017238427A Active JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法
JP2020037396A Pending JP2020109101A (ja) 2012-08-14 2020-03-05 幹細胞増強治療法
JP2021181985A Pending JP2022025136A (ja) 2012-08-14 2021-11-08 幹細胞増強治療法

Country Status (8)

Country Link
US (2) US9932407B2 (enExample)
EP (1) EP2885000A4 (enExample)
JP (4) JP6664219B2 (enExample)
CN (3) CN104717980A (enExample)
AU (2) AU2013302620B2 (enExample)
CA (1) CA2882222A1 (enExample)
IL (1) IL237228B (enExample)
WO (1) WO2014028668A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
JP6895890B2 (ja) * 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
JP7197078B2 (ja) * 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
CN112105380A (zh) * 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN113727602B (zh) 2019-02-04 2023-10-03 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
IL298780A (en) 2020-06-08 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505566A1 (en) * 1989-12-15 1992-09-30 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
EP2329822A1 (en) * 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2006504630A (ja) * 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
EP1536814A4 (en) * 2002-07-03 2006-02-15 Immunogen Inc ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US20090075926A1 (en) 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
KR20140101876A (ko) * 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
EA026732B1 (ru) * 2009-06-11 2017-05-31 Минерва Байотекнолоджиз Корпорейшн Способы культивирования стволовых клеток и клеток-предшественников
US20120156246A1 (en) * 2010-06-16 2012-06-21 Bamdad Cynthia C Reprogramming cancer cells

Similar Documents

Publication Publication Date Title
JP2015526446A5 (enExample)
Gonzalez-Sanchez et al. The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
Kawaguchi et al. SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup
Takahashi et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer‐hybrid epitope long peptide of MAGE‐A4 cancer antigen
JP2016519933A5 (enExample)
JP2019516663A5 (enExample)
JP2019519215A5 (enExample)
EA202190587A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
JP2020506690A5 (enExample)
JP2019536426A5 (enExample)
JP2012102122A5 (enExample)
AU2012342117A8 (en) Recombinant proteins and their therapeutic uses
JP2015506961A5 (enExample)
JP2019520038A5 (enExample)
RU2019113989A (ru) Лекарственное средство
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
Lin et al. Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
JP2019531254A5 (enExample)
JP2019520059A5 (enExample)
EA202190572A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы
Brunekreeft Re-activation of anti-tumor immunity in cancer by target-restricted activation of receptors of the Tumor Necrosis Factor-family
EA201992417A1 (ru) Пептиды и их комбинации для применения в иммунотерапии раковых заболеваний